Baird Capital Invests in Prescient Healthcare Group
Baird Capital, the direct investment arm of Robert W. Baird & Co., announced today that it has acquired an interest in Prescient Healthcare Group (Prescient). Prescient is a leading product strategy consultancy to the global biopharmaceutical industry. As part of the transaction, Baird Capital Partner Andrew Ferguson and Principal John DiGiovanni will join the Prescient board of directors. Nick Edwards, founder and former Chairman of Kinapse, will chair the board.